Senior Director, Medical Affairs, Midsized Markets Europe

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, GM, Midsized Markets, the Senior Director, Medical Affairs, Midsize Markets Europe, is the medical leader responsible for defining and executing the medical strategy for oncology products in our portfolio within Midsized markets. This role serves as the medical voice within the Midsized markets Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that Midsized markets medical considerations are embedded in the regional medical strategy and plans and will partner with the Midsized markets country managers and crossfunctional teams, as well as VP Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the Midsized markets medical team and working closely with the Global, Regional, Country Medical Affairs teams across Med Affairs functions. Responsibilities: Act as the Medical lead for Midsized Markets, accountable for medical strategy, execution, and impact across the RevMed portfolio. Serve as a core member of the Midsized Markets Leadership Team, contributing insights to medical and clinical development strategy, launch planning, and business decisions. Establish Midsized markets medical strategy across pre-launch, launch, and post-launch phases. Oversee all aspects of medical strategy and execution in Midsized markets. Cross-functionally align efforts seamlessly with access, regulatory, and commercial objectives while building and executing upon the medical plan. Collaborate effectively with regional and global teams by contributing to overall medical strategy, strongly partnering with local, regional and global clinical development and operations teams. Translate global medical and clinical strategies into relevant medical strategy. Represent the company as the senior medical expert within the local oncology and scientific community, acting as a spokesperson for Midsized markets. Gather, analyze and interpret clinical data, providing strategic insights to inform critical decisions. Build strong relationships with national key opinion leaders, oncology networks, academic institutions, and scientific societies. Lead scientific exchange, advisory boards, investigator and other external meetings, press conferences, and congress engagement at country level. Provide medical leadership on evidence generation activities including local studies, real-world evidence initiatives, and investigator-initiated research (where permitted). Ensure effective execution of publication plans and scientific communication activities. Lead medical launch readiness for oncology products, including training, scientific materials, and field medical engagement plans. Partner with Market Access and Commercial country and regional teams to support value communication and reimbursement-related interactions from a medical perspective, e.g. representing and defining evidence and value of innovation at oral HTA hearings. Support lifecycle management activities including new indications, label updates, and competitive positioning. Provide medical review and approval of non-promotiona